News coverage about Seres Therapeutics (NASDAQ:MCRB) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Seres Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.1022313888411 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s analysis:

Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 0.81% during trading on Tuesday, hitting $14.68. The stock had a trading volume of 20,077 shares. Seres Therapeutics has a 52-week low of $8.85 and a 52-week high of $15.09. The firm’s 50-day moving average is $13.62 and its 200 day moving average is $11.21. The firm’s market cap is $594.72 million.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.00 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. Seres Therapeutics’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter last year, the company earned ($0.70) earnings per share. On average, analysts expect that Seres Therapeutics will post ($2.48) EPS for the current year.

MCRB has been the topic of several recent research reports. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Wednesday, July 5th. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Friday, May 19th. BidaskClub raised Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $19.00 target price (up previously from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $17.00.

TRADEMARK VIOLATION NOTICE: “Seres Therapeutics (MCRB) Earning Somewhat Favorable News Coverage, Analysis Finds” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Insider Buying and Selling by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.